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Glomerular hemodynamics and the renin-angiotensin system sion, and the beneficial action of angiotensin-converting-
in patients with type 1 diabetes mellitus. enzyme (ACE) inhibition on the kidney involves prefer-
Background. Many studies have reported that blocking the ential efferent arteriolar dilation [1–6]. A related ele-renin-angiotensin-system (RAS) with an angiotensin-convert-
ment is the suggestion that the effects of ACE inhibitioning enzyme (ACE) inhibitor or an angiotensin receptor blocker
on kinin metabolism also contribute to efferent arteriolarin the patient with diabetes mellitus leads to an increase in
renal plasma flow (RPF), no change in glomerular filtration dilatation as a major part of therapeutic efficacy [7–11].
rate (GFR), and a fall in filtration fraction. This constellation is As the construct is simple and easy to understand,
generally attributed to predominant efferent arteriolar dilation. logical and internally consistent, and supported by sub-
Methods. This study examined the renal hemodynamic re-
stantial data, it has been subject to little thoughtful criti-sponse to blocking the RAS with both captopril and candesartan
cism. We were surprised, therefore, by the fact that theon separate days in 31 patients with type 1 diabetes mellitus.
Results. There was a wide range of changes in RPF and angiotensin II subtype 1 (AT1) receptor blocker, irbesar-
GFR in response to the two agents, each administered at the tan, not only increased renal plasma flow (RPF) in pa-
top of its dose-response range. The RPF response to the two tients with type 2 diabetes mellitus and nephropathy, it
agents was strongly concordant (r  0.65; P  0.001), as was
also increased glomerular filtration rate (GFR) substan-the GFR response (r  0.81; P  0.001). Moreover, there was
tially in some patients [12]. Indeed, experts in the fielda strong correlation between the RPF response and the change
in GFR with each agent (r  0.83 and 0.66; P  0.01). A expressed concern that an increase in GFR might limit
significant rise in RPF was followed by a rise in GFR. The the therapeutic efficacy of AT1 receptor blockers in such
RPF dependency of GFR in the type 1 diabetics suggests patients. We now know that AT1 receptor blockers arestrongly that glomerular filtration equilibrium exists in the glo-
effective in decreasing progression of ESRD [13–15],meruli of the diabetic kidney: Simple notions of local control
especially so early in the course [13] when the rise inbased on afferent:efferent arteriolar resistance ratios are too
simplistic. GFR was most striking in our studies [12]. There are
Conclusion. Our data suggest that the intrarenal RAS is alternatives to afferent and efferent-resistant ratios in
activated in over 80% of patients with type 1 diabetes mellitus. the control of GFR [16, 17], the subject of this study.
Abundant evidence suggests that this activation predisposes
Measurements of the renal clearance of markers ofto diabetic nephropathy.
RPF and GFR—the only approach currently available
for their assessment in the intact human—have long been
believed to enjoy a rather limited signal-to-noise ratioA construct explaining glomerular hemodynamics in
[18]. We were surprised, therefore, by the remarkablethe kidney at risk of progression to end-stage renal dis-
intra-individual concordance of changes in para-amino-ease (ESRD) is so widely held today that it seems to hold
hippurate (PAH) clearance in response to an ACE inhib-the status of received truth. According to this concept a
itor and a renin inhibitor in healthy humans [19], and topreferential action of angiotensin II (Ang II) on the
an AT1 receptor blocker and ACE inhibitor in patientsefferent arteriole contributes to glomerular hyperten-
with type 1 diabetes mellitus [20]. Moreover, the rise in
RPF in some patients with diabetes mellitus was suffi-
cient [12, 20] to influence GFR if RPF dependency ofKey words: ACE-I, angiotensin receptor blockade, intrarenal renin
system, filtration equilibrium. GFR existed in that setting. Thus, we undertook this study
with two goals in mind: (1), to examine the RPF depen-Received for publication February 21, 2002
dency of GFR in type 1 diabetes mellitus; and (2), toand in revised form May 14, 2002
Accepted for publication August 5, 2002 exploit studies in which the response to an ACE inhibi-
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was compared systematically to provide an index of the where balance was achieved on a controlled diet. All
subjects were placed on a high-salt isocaloric diet startingreproducibility of the clearance measures, and to ascer-
tain the mechanism of the ACE inhibitor-induced re- two days prior to admission and continuing throughout
the hospitalization, with a daily sodium intake of 200 mmol.sponses. Specifically of interest was the question of
whether the reduction of Ang II formation induced by Daily dietary potassium (100 mmol) and fluid intake
(2500 mL) were constant. Twenty-four-hour urine sam-the ACE inhibitor could account for this effect.
ples were collected daily and analyzed for sodium, potas-
sium, creatinine and protein. Twenty-four-hour urine so-
METHODS
dium and potassium content was expected from the diet
Subjects and protocols (Table 1), as were PRA and plasma aldosterone concen-
trations. The protocol was approved by the Human Sub-A total of 31 men and women with type 1 diabetes
mellitus were studied who were admitted sequentially jects Committee of the institution, and written informed
consent was obtained from each subject.to this study. They ranged in age from 17 to 62 years
(mean  SEM; 31  2.2). The duration of diabetes
Renal hemodynamic and hormonal responses to theranged from 2 to 40 years (mean 17 1.9). Type 1 diabetes
ACE inhibitor, captopril and the AT1 receptormellitus was diagnosed according to accepted guidelines
blocker, candesartan[21]. Body weight ranged from 55 to 110 kg with an
average of 73.5  2.1 kg. Body mass index ranged from Each subject participated in two experimental days.
On the morning of each study day an intravenous cathe-21.7 to 35.6 kg/m2 with an average of 25.5  0.61 kg/m2.
Body mass index exceeded 28 in four of the patients. ter was placed in each arm of each subject, one for
infusion of PAH, inulin, and dextrose 5% in water andBlood pressure averaged 120  2.8/69  1.5 mm Hg,
and exceeded a systolic BP of 135 mm Hg in four. Dia- the other for blood sampling. A third intravenous line
was placed for continuous infusion of insulin that wasstolic BP did not exceed 85 mm Hg in any patient. Hemo-
globin A1C (HbA1c) ranged from 4.8 to 10.7%, and aver- started at 0.015 units/kg/h. Blood glucose was measured
every 30 minutes (Precision PCX; Abbott Laboratories,aged 7.7 0.28%. Hemoglobin A1c exceeded 9% in four
subjects. Similarly, fasting blood sugar averaged 144  Chicago, IL, USA). The insulin infusion was adjusted to
maintain blood glucose below renal threshold but with-8.8 mg/dL, exceeding 200 mg/dL in three. Serum creati-
nine concentration was less than 1.4 mg/dL in all but out inducing hypoglycemia, at levels of about 100 to 140
mg/dL. The subjects were supine and had been fastingone patient in whom serum creatinine was 2.0 mg/dL.
All were otherwise healthy, free of sustained proteinuria for at least eight hours. Each study day began with a 60-
minute baseline infusion of PAH and inulin prior to drugand other complications of diabetes. Three 24-hour urine
collections were made in search of microalbuminuria. administration, to determine baseline renal plasma flow
(RPF) and glomerular filtration rate (GFR) respectively.We identified microalbuminuria, reflecting a value ex-
ceeding 17 g/mg creatinine in males, and 25 g/mg Hormonal measurements were made on blood samples
obtained at baseline and four hours after drug adminis-creatinine in females in five subjects. In three of the five,
all three urine collections showed microalbuminuria. In tration while the subjects were lying supine. Peak RPF
was identified as the two largest sequential measures ofthe other two subjects, two of the three collections showed
an increase. There was no difference in the renal vascular PAH clearance. The term “peak GFR” designates GFR
measurements made at the same time as peak RPF.response to pharmacological interruption of the renin-
angiotensin-system in those with microalbuminuria, and The study was designed to compare the renal hemody-
namic response to captopril and to candesartan. On thethose who lacked it. There were five patients in whom
hypertension had been diagnosed. In each, treatment first morning the patients received captopril, 25 mg PO.
On the next morning, the patients received candesartan,involved an ACE inhibitor or an angiotensin antagonist,
and in three additional patients who were free of hyper- 16 mg PO. These doses were chosen because both repre-
sent the top of the relationship between dose and RPFtension, ACE inhibition had been undertaken as a pro-
phylactic. ACE inhibitors and angiotensin antagonists response.
Blood pressure was recorded during each infusion bywere discontinued 10 days before the renal hemodynamic
study. Our study plan included the use of alpha methyl- an automatic recording device (Dinamap; Critikon, Nor-
derstedt, Germany) at five-minute intervals.dopa to control hypertension should therapy be needed,
but in no case was it required. There was no difference
Renal clearance studiesin the renal vascular response to blocking the renin sys-
tem in those with or without hypertension or prior ACE Para-aminohippurate (Merck, Sharp & Dohme, Rah-
way, NJ, USA) and inulin (Inutest; Fresenius Pharmainhibitor use. The subjects were studied during admission
to a metabolic ward at the General Clinical Research Austria GmbH, Linz, Austria) clearances were assessed
after metabolic balance was achieved. A control bloodCenter (GCRC) at the Brigham and Women’s Hospital
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Table 2. Baseline renal hemodynamics of 31 subjects in highTable 1. Baseline characteristics of 31 subjects in high sodium balance
sodium balance
Parameters Mean  SEM
Captopril vs.
Age years 312.2 candesartan
Sex distribution male/female 13/18 Captopril Candesartan P value
Race All Caucasian
Body mass index kg/m2 25.50.61 Renal plasma flow
mL/min/1.73 m2Systolic blood pressure mm Hg 1202.8
Diastolic blood pressure mm Hg 691.5 Baseline 57720 59421 0.6
Glomerular filtration rateDuration of diabetes years 171.9
Hemoglobin A1C % 7.70.3 mL/min/1.73 m2
Baseline 1174 1184 0.6Fasting blood sugar mg/dL 1448.8
Serum creatinine mg/dL 0.90.04
Serum sodium mEq/L 1381
Serum potassium mEq/L 4.30.1
24-hour urine sodium mEq 26320
24-hour urine potassium mEq 594 vascular and PRA responses to captopril and candesar-
Plasma renin activity ng/Ang I/mL/h 0.50.2
tan. The subjects were then divided into two groups,Plasma aldosterone ng/dL 3.00.2
those in whom the RPF response to captopril was normal
and those in whom the response was accentuated, to
determine if there were differences in renin activity. Fish-
er’s exact test, t test and Mann-Whitney rank sum testsample was drawn, and then loading doses of PAH (8
were used to compare the characteristics and the renalmg/kg) and inulin (50 mg/kg) were given intravenously.
hemodynamic and PRA responses of these two groups.A constant infusion of PAH and inulin was initiated
Analysis of covariance (ANCOVA) was performed toimmediately at a rate of 12 mg/min and 30 mg/min, re-
account for possible confounding effects of baseline char-spectively, with an IMED pump (IMED Corp., San
acteristics on RPF responses on the two study days.Diego, CA, USA). This achieved a plasma PAH concen-
tration in the middle of the range in which tubular secre-
tion dominates excretion. At this plasma level of PAH, RESULTS
clearance is independent of plasma concentration, and Baseline characteristics of the subjects are listed in
represents about 90% of RPF when corrected for indi- Table 1. The high salt balance, as evidenced by a 24-
vidual body surface area. Likewise, at the level of plasma hour urine sodium excretion of 263  20 mEq, resulted
inulin achieved, inulin clearance reflects GFR. RPF and in suppression of PRA at baseline, as anticipated.
GFR determinations were made at baseline and at 45- Renal plasma flow at baseline was not significantly
minute intervals thereafter until 225 minutes (4 h) different for captopril and candesartan (Table 2). Both
while the subjects were supine. captopril and candesartan caused a significant rise in
RPF. Following captopril RPF rose by 66  11 mL/min/Laboratory procedures
1.73 m2 (P 0.01). Renal plasma flow rose by more than
Blood samples were collected on ice and spun immedi- 20 mL/min/1.73 m2—the upper limit of the response in
ately, and the plasma was frozen until assay. Urinary so- normal subjects of the renal vascular response to capto-
dium and serum potassium levels were measured using the pril on a high salt diet—in all but 6 of the 31 subjects.
ion-selective electrode (ISE). PAH and inulin were mea- Candesartan likewise induced a substantial rise in RPF
sured using an autoanalyzer technique. Plasma renin ac- of 88  12 mL/min/1.73 m2 (P  0.001). The same six
tivity (PRA) and aldosterone were determined by radio- subjects showed limited responses to candesartan. The
immunoassay [22, 23]. Hemoglobin A1C was measured response to captopril and candesartan were highly corre-
by high performance liquid chromatography (HPLC). The lated (Fig. 1; r  0.65; P  0.001).
normal range is 4.4 to 6.3%. Baseline and peak GFR values were likewise not sig-
nificantly different between the two drugs. There was no
Statistical analyses significant change in GFR, on average, either in response
Group means were calculated with the standard error to captopril or to candesartan (P  0.74 and P  0.45,
of the mean (SEM) as the index of dispersion. For renal respectively). By analogy with the RPF response to cap-
hemodynamics data, the baseline value taken was the topril and to candesartan, GFR responses to both agents
average of three pre-drug determinations, and the peak were also highly correlated (Fig. 2; r  0.81; P  0.001).
response was the average of the two highest consecutive Individuals in whom captopril seemed to raise GFR also
values. showed a rise in GFR with candesartan. The individuals
Pearson’s correlation was used to test the association in whom captopril appeared to drop GFR also showed
of the renal response to candesartan with the response a drop with candesartan.
There was a clear correlation between the renal vaso-to captopril. Paired t test was used to compare the renal
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Fig. 1. Renal plasma flow of captopril versus candesartan. Relationship
between the renal hemodynamic response to angiotensin-converting
enzyme (ACE) inhibition by captopril, and to angiotensin II type 1
(AT1) receptor blockade by candesartan in 31 patients with type 1
diabetes mellitus. Note the concordance between the renal hemody-
namic response to captopril and to candesartan (r  0.65; P  0.001;
y  0.75x  28.90; f  20.9).
Fig. 3. PAH versus inulin. (A ) Relationship between renal plasma
flow (RPF) response to candesartan as measured by PAH clearance, and
simultaneous change in glomerular filtration rate (GFR) as measured by
inulin clearance. Note the large increases in RPF were associated with
a substantial increase in GFR (r  0.83; P  0.01), evidence of the
RPF dependency of GFR in this situation. (B ) Relationship between
RPF response to captopril in the same patients, and its influence on
GFR. Note the similar relationship between RPF and GFR following
captopril (r  0.66; P  0.01): GFR changes are RPF-dependent.Fig. 2. Glomerular filtration rate of captopril versus candesartan. Rela-
tionship between changes in glomerular filtration rate (GFR) induced
by candesartan and by captopril in the same patients as in Figure 1.
Note that the responses to the two agents show close accord (r  0.81;
P  0.001; y  0.91x  2.75; f  48.3; N  28). When GFR rose in topril and candesartan differed from the others in severalresponse to captopril, it also rose in response to candesartan. When
possibly important ways. They were older (38 6 vs. 27GFR fell in response to captopril, it also fell in response to candesartan.
2 years), had a longer duration of diabetes mellitus (27
5 vs. 15  2 years), and despite the increased duration
were still free of proteinuria and hypertension. They did
dilator response to candesartan, indicated by a change not differ from the others in the indices of glycemic control.
in RPF, and the change in GFR (Fig. 3A; r  0.83; P 
0.001). The individuals in whom GFR rose were largely
DISCUSSIONthose in whom candesartan induced a substantial rise in
RPF. Similar relationships were evident between the On average, both captopril and candesartan induced a
renal hemodynamic response to captopril and the influ- significant increase in RPF in patients with type 1 diabetes
mellitus. Again, on average GFR neither rose nor fell, asence of captopril on GFR (Fig. 3B; r  0.66; P  0.002).
Although it was not the primary focus of this study, reported in many studies [2–6]. The strong concordance
between the RPF response induced by captopril and byit was evident that the six individuals who failed to show
an enhanced response to blockade of the RAS with cap- candesartan indicates that the rise in RPF in individual
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patients probably reflects a reversal of angiotensin-medi- effect on GFR [18, 31, 32]. This favors glomerular filtra-
tion disequilibrium in normal humans. With the develop-ated vasoconstriction, as suggested earlier [20]. What is
new is the finding that the change in GFR induced by ment of diabetes mellitus, there is a substantial increase
in both renal and glomerular size, with concomitantcaptopril and by candesartan was also highly concordant,
suggesting that these changes are equally real. When changes in the glomerular capillaries. The findings in this
study raise the interesting possibility that one physiologi-captopril induced a sharp increase in GFR, so did cande-
sartan. The equally strong concordance between change cal consequence of this morphologic change is the devel-
opment of glomerular filtration equilibrium, and thusin RPF and change in GFR also induced by both capto-
pril and candesartan is supportive of this hypothesis, and RPF dependency of GFR. The fact that diabetes mellitus
is a volume expanded state, also would favor filtrationsuggests a responsible mechanism: In the setting of this
study, GFR was to a major degree RPF dependent. equilibrium. There are alternatives to filtration equilib-
rium as an explanation for the rise in GFR. GlomerularRenal plasma flow dependency of GFR, which occurs
in some circumstances but not all, has been understood intermittency, which was corrected by ACE inhibition
and angiotensin receptor blockade, would provide anfor thirty years [24–26]. Glomerular filtration occurs be-
cause hydrostatic pressure in the glomerular capillaries alternative explanation. There is little evidence of glo-
merular intermittency in species beyond the amphibianexceeds the offsetting oncotic pressure due to intravascu-
lar plasma protein. As filtration occurs, protein concen- [18], and intermittency would be especially unlikely in
view of the very high baseline GFR.tration in the glomerular capillaries rises, and filtration
will cease when oncotic pressure equals glomerular capil- Why have these relationships been missed in earlier
studies? In general, the renal hemodynamic response tolary hydrostatic pressure. This equality between the two
offsetting forces has been referred to as “filtration pres- ACE inhibition or angiotensin receptor blockers in the
patients with renal disease or at risk of renal injury hassure equilibrium.” This state, which has been observed
in the hydropenic rat [26] and hydropenic monkey [27], been presented as group means. When examined in this
way, we found in our current study what others haveis a situation in which an increase in glomerular plasma
flow rate, in the absence of significant changes in protein found and reported in the past: RPF rose, GFR on aver-
age did not change, and as a consequence filtration frac-oncotic or capillary hydrostatic pressure, will result in a
proportional rise in GFR. This rise occurs because an tion fell. Over the past decade, however, we have come
to appreciate that the clearance method, performed care-increase in plasma flow, in the absence of other changes
in the determinants of GFR, results in a reduction in the fully, is sufficiently precise that it can be applied to the
individual measure. In a double blind comparison inrate of increased plasma protein concentration. As a
consequence, the point at which filtration equilibrium is healthy humans we found a striking concordance be-
tween renal responses to captopril and to a renin inhibi-achieved is moved further toward the efferent end of
the glomerular capillary network, effectively increasing tor [19]. More recently, we found equivalent concor-
dance to the renal vascular response to captopril and tothe total capillary surface area exposed to a positive
ultrafiltration pressure. The striking concordance be- the AT1 receptor blocker candesartan in patients with
type 1 diabetes mellitus [20]. Indeed, it was the findingstween the change in RPF induced by both candesartan
and captopril, and what is probably the consequent in the latter study that led to the current analysis. The
variations found in individual patients in this study arechange in GFR, suggests strongly that the changes in
GFR reflect RPF dependency. real, and may well reflect different stages in the process
or different background pathophysiology.Whether or not filtration equilibrium exists appears
to vary both with physiological state and the species. In Although it was not our primary goal in this study to
identify the factors responsible for a large renal hemody-the dog, filtration disequilibrium is the usual finding, and
GFR varies little with RPF, for example, during plasma namic response to blocking the RAS in some patients,
and in minimal response in others, we did note thatvolume expansion [28]. In the hydropenic rat, as indi-
cated earlier, filtration equilibrium is the routine. With the nonresponders tended to be older, have a longer
duration of diabetes mellitus, and to have remained com-volume expansion, on the other hand, at least some rats
achieve filtration disequilibrium [17]. In humans, of course, plication free. One intriguing possibility is that these
factors are mechanistically linked: Specifically, one mightonly indirect evidence is available. More than sixty years
ago, Homer Smith and coworkers suggested that filtra- argue that the prolonged duration at risk without devel-
opment of nephropathy is a product of the fact that theytion equilibrium was the usual situation in the healthy
human kidney [29], a conclusion not confirmed by more did not activate the RAS, and thereby were protected.
An alternative possibility is that they escaped nephropa-recent analyses [30]. In accord with the latter, volume
expansion and blocking the renin-angiotensin system thy for other reasons, and the RAS activation burned
out during that long interval. While we find the former(RAS) with ACE inhibitors or angiotensin receptor block-
ers will increase RPF in healthy humans but have little possibility to be the more attractive, no information in-
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trinsic to this study would allow us to choose. Three at the tissue level. As the RAS clearly contributes to the
development and progression of nephropathy in diabe-major clinical subsets of patients, involving whether an
enhanced renal vascular response was present; whether tes, identification of the sources of the intrarenal RAS
activation has a substantial priority.hypertension was present; and whether microalbumin-
uria was present was examined in this study, but as only
five or six patients fell into these subsets, any conclusion ACKNOWLEDGMENTS
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